Konstantin Konstantinov
Director/Board Member at REPLIGEN CORPORATION
Net worth: 224 382 $ as of 2024-03-30
Profile
Konstantin Konstantinov is an Independent Director at Repligen Corp., an Operating Partner at Flagship Pioneering, and the Chief Technology Officer at Ring Therapeutics, Inc. He previously worked as the Vice President at Genzyme Corp., Head of Process Sciences at Bayer Healthcare Pharmaceuticals LLC, and Senior VP of Manufacturing & Process Sciences at Codiak BioSciences, Inc. Konstantinov holds a doctorate degree from Osaka University and undergraduate and graduate degrees from Technical University of Sofia.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
REPLIGEN CORPORATION
0.00% | 2024-03-17 | 1,220 ( 0.00% ) | 224 382 $ | 2024-03-30 |
Konstantin Konstantinov active positions
| Companies | Position | Start |
|---|---|---|
| REPLIGEN CORPORATION | Director/Board Member | 2022-05-25 |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 2023-06-06 |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 2023-06-06 |
Former positions of Konstantin Konstantinov
| Companies | Position | End |
|---|---|---|
| Bayer Healthcare Pharmaceuticals LLC | Corporate Officer/Principal | 2006-12-31 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| CODIAK BIOSCIENCES | Chief Tech/Sci/R&D Officer | - |
Training of Konstantin Konstantinov
| Osaka University | Doctorate Degree |
| Technical University of Sofia | Graduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| REPLIGEN CORPORATION | Health Technology |
| Private companies | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
| Bayer Healthcare Pharmaceuticals LLC | |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Ring Therapeutics, Inc.
Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Konstantin Konstantinov
